ASCO Day 3 Highlights: RevMed's Progress and Challenges for Akeso
On the third day of ASCO, RevMed received significant praise for its advancements in pancreatic cancer treatment, while Akeso faced disappointing news.
Editorial Staff
1 min read
Updated 9 days ago
The third day of the ASCO conference showcased a notable breakthrough in pancreatic cancer treatment, particularly highlighting the achievements of RevMed.
In contrast, Akeso and Summit experienced setbacks, raising concerns about their current trajectories in the competitive landscape of cancer therapies.
Additionally, a new approach to immunotherapy was introduced, suggesting potential shifts in treatment paradigms moving forward.